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http://www.jnanobiotechnology.com/content/11/1/32RESEARCH Open AccessAge-dependent effects of microglial inhibition
in vivo on Alzheimer’s disease neuropathology
using bioactive-conjugated iron oxide
nanoparticles
Micaela Glat1†, Hadas Skaat2†, Noa Menkes-Caspi1, Shlomo Margel2 and Edward A Stern1,3*Abstract
Background: Tau dysfunction is believed to be the primary cause of neurodegenerative disorders referred to as
tauopathies, including Alzheimer’s disease, Pick’s disease, frontotemporal dementia and Parkinsonism. The role of
microglial cells in the pathogenesis of tauopathies is still unclear. The activation of microglial cells has been
correlated with neuroprotective effects through the release of neurotrophic factors and through clearance of cell
debris and phagocytosis of cells with intracellular inclusions. In contrast, microglial activation has also been linked
with chronic neuroinflammation contributing to the development of neurodegenerative diseases such as
tauopathies. Microglial activation has been recently reported to precede tangle formation and the attenuation of
tau pathology occurs after immunosuppression of transgenic mice.
Methods: Here we report the specific inhibition of microglial cells in rTg4510 tau-mutant mice by using fibrin
γ377-395 peptide conjugated to iron oxide (γ-Fe2O3) nanoparticles of 21 ± 3.5 nm diameter.
Results: Stabilization of the peptide by its covalent conjugation to the γ-Fe2O3 nanoparticles significantly decreased
the number of the microglial cells compared to the same concentration of the free peptide. The specific microglial
inhibition induces different effects on tau pathology in an age dependent manner. The reduction of activation of
microglial cells at an early age increases the number of neurons with hyperphosphorylated tau in transgenic mice.
In contrast, reduction of activation of microglial cells reduced the severity of the tau pathology in older mice. The
number of neurons with hyperphosphorylated tau and the number of neurons with tangles are reduced than those
in animals not receiving the fibrin γ377-395 peptide-nanoparticle conjugate.
Conclusions: These results demonstrate a differential effect of microglial activity on tau pathology using the fibrin
γ377-395 peptide-nanoparticle conjugate, depending on age and/or stage of the neuropathological accumulation
and aggregation.
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Tau protein is present in phosphorylated and aggregated
form in Alzheimer’s disease (AD) and in a group of neuro-
degenerative disorders collectively termed tauopathies [1].
Tau is a microtubule-associated protein (MAP) that
under normal physiological conditions is involved in micro-
tubule assembly and stabilization [2,3]. In the normal adult
human brain, six isoforms of tau are produced from a single
gene by alternative mRNA splicing in exons 2, 3, and 10 of
the tau gene located on chromosome 17 [4,5]. Tau occurs
mainly in axons, whereas another MAP protein, MAP2, is
localized to the somatodendritic compartment [6].
Tauopathies are characterized by an abnormal hyper-
phosphorylation of the tau protein in sites not normally
phosphorylated and later assembled into neurofibrillary
tangles (NFTs) in neuronal cell bodies and sometimes in
glial cells [7]. Early hyperphosphorylation is facilitated by
kinases such as glycogen synthase kinase 3 (GSK3), cyclin-
dependent kinase 5 (cdk5) and c-Jun N-terminal kinase
(JNK) [8,9]. Hyperphosphorylation and the formation of
NFTs create conditions in which the tau protein is unable
to bind with microtubules, producing impairments in
axonal trafficking and profound effects on the function and
viability of neurons, contributing to synaptic dysfunction
and neurodegeneration [10-12].
Microglial cells are the resident immune cells of the
CNS [13,14]. Under physiological conditions, residential
microglial cells are quiescent and scattered throughout
the CNS [15], and are characterized by a small cell body
and a ramified morphology. Occasionally, microglia will
become moderately activated in order to play the classic
role as “scavengers” for the maintenance and restoration
of the CNS. They begin to proliferate, changing their
morphology into an amoeboid shape and phagocytose
cells that are pathologically damaged or developmentally
unnecessary [16]. These functions of microglia are con-
trolled by communication with cytokines, chemokines,
trophic factors, and other neuromodulating molecules
among neurons, astrocytes and microglia [17].
Several studies have shown that microglial cells are bene-
ficial for the proper function of the CNS through phagocyt-
osis of cell debris [18-20]. It has been suggested that this
phagocytic activity plays a fundamental role in facilitating
reorganization of neuronal circuits and triggering repair in
neurodegenerative diseases. Furthermore, it was shown
that insufficient clearance by microglia, prevalent in tau
pathology and declining with age, is associated with an in-
adequate regenerative response [21]. Activated microglial
cells have also been reported to possess neuroprotective/
neurotrophic effects in vitro [22]. Activated microglia could
secrete some neurotrophic factors such as NGF, NT-3 and
BDNF which have been demonstrated to be neuroprotective
[23]. However, other studies have shown that inflammation
plays a key role in the progression of neurodegenerativediseases such as AD. In an animal model of tauopathies,
early microglial activation was associated with loss of synap-
ses preceding tangle formation, suggesting that microglial
activation is a cause of neuronal degeneration rather than a
consequence of it [24-26]. Therefore, controversy exists
about the role microglial function plays in the development
of the progression of neurodegenerative diseases, driving the
need for a more precise method of testing microglial func-
tion. To do so, we have utilized a specific inhibitor of micro-
glial cells, the fibrinogen-derived γ377-395 peptide, for the
inhibition of microglial cells at various stages of the
tauopathy disease.
The fibrinogen-derived γ377-395 peptide has been re-
cently reported as a specific inhibitor of microglial acti-
vation via the MAC-1 receptor (αMβ2, CD11b/CD18)
[27,28]. The main disadvantage of fibrin γ377-395 peptide
is its short in vivo half-life time due to rapid enzymatic
degradation, leading to loss of biological activity and
functions. It requires, therefore, frequent direct injec-
tions of the peptide in order to maintain its bioavaila-
bility necessary for microglia inactivation. However,
repeated direct intracranial administration may lead to
undesirable systematic effects and toxicity. To obtain a
steady administration over-time, peptides are adsorbed
onto, or encapsulated within, nano-materials to protect
their stability and biological activity in a sustained and
controllable manner [29].
Magnetic iron oxide (maghemite, γ-Fe2O3) nanoparticles
are particularly promising due to their high surface area to
volume ratio, magnetic properties, biocompatibility, rela-
tive non-toxicity, and biodegradability. The use of iron
oxide magnetic nanoparticles for various biomedical appli-
cations, e.g., hyperthermia, diagnosis, cell-labeling and
sorting, DNA separation, MRI contrast agents and drug
delivery, have already been demonstrated [30-35].
In this study, we present a novel approach for specific
inhibition of microglial cells in rTg4510 tau-transgenic
mice by using fibrin γ377-395 peptide-conjugated γ-Fe2O3
nanoparticles of 21 ± 3.5 nm diameter. The stabilization
of the peptide by its conjugation to these nanoparticles
significantly decreased the number of the microglial cells
compared to the same concentration of the free peptide.
Furthermore, the specific inhibition of microglial cells,
attained using the γ377-395 peptide-conjugated γ-Fe2O3
nanoparticles, was found to have a dual effect on tau
pathology depending on the age of the mice used in the
study.
Results
Specific inhibition of microglial cells using fibrin γ377-395
peptide-conjugated γ-Fe2O3 nanoparticles
The fibrin derived γ377-395 peptide has been shown to
specifically inhibit microglial activity in vivo [28] and
was therefore chosen to facilitate the specific inhibition
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short half-life when administered in saline solution and
needs to be administered constantly as a result. To
counteract this issue, we have conjugated the peptide to
γ-Fe2O3 nanoparticles. The transmission electron micro-
scope (TEM) image of the fibrin γ377-395 peptide-
conjugated γ-Fe2O3 nanoparticles shown in Figure 1
demonstrates that these nanoparticles are stable against
agglomeration and possess a diameter of 21 ± 3.5 nm.
These nanoparticles have been shown to enhance effi-
cacy of delivery of bioactive material and to provide
protection against biodegradation [36]. Fibrin γ377-395
peptide, once conjugated to the nanoparticles, is retained
in the site of injection and does not disperse by diffu-
sion. This was confirmed 30 days post intracranial injec-
tion, using potassium ferrocyanide staining, which gave
a positive staining with brains treated with the conjugated
peptide, whereas no positive staining was seen in brain
hemispheres injected with saline or free fibrin γ377-395
peptide (Figure 2).
To determine the effect of fibrin γ377-395 peptide on
activation of microglial cells, we measured the average
numbers of activated microglial cells per area in ani-
mals injected with saline versus fibrin γ377-395 peptide-
conjugated γ-Fe2O3 nanoparticles, as well as free fibrin
γ377-395 peptide. We were unable to determine the spe-
cificity of fibrin γ377-395 peptide-conjugated γ-Fe2O3 nano-
particles to the microglia. Figure 3 shows examples of
activated microglia cells using IB4, a lectin which stains
activated microglia. The data were analyzed with a 2-wayFigure 1 TEM image of the fibrin γ377-395 peptide-conjugated
γ-Fe2O3 nanoparticles. The transmission electron microscope (TEM)
image of the fibrin γ377-395 peptide-conjugated γ-Fe2O3
nanoparticles demonstrates that these nanoparticles are stable
against agglomeration and possess a diameter of 21 ± 3.5 nm.analysis of variance (ANOVA). The fibrin γ377-395 peptide,
when conjugated to the nanoparticles, significantly reduced
the number of activated microglia (white arrows) in the site
of injection compared to saline (Figure 3, top 2 rows), (F =
41.01; (degrees of freedom (df) = 1,274; p ≤ 0.05). An effect
of age was also found (F = 74.89; df = 1,274; p ≤ 0.05). In
addition, we also found an interaction effect between age
and treatment (F = 4.25; df = 1,274; p ≤ 0.05). These results
are summarized in the graphs in Figure 4A. Whereas in
both the saline-injected and fibrin γ377-395 peptide-injected
animals, the number of activated microglia increased with
age, the rate of increase was reduced in the fibrin γ377-395
peptide-injected animals, indicating that the conjugated
fibrin γ377-395 peptides reduces the rate of activation of
microglial cells. The γ-Fe2O3 nanoparticles have been
shown to be an effective mechanism of delivery for peptides
in the mammalian brain [37,38]. The nanoparticles alone
showed no effects, and no neurotoxicity effects of the
nanoparticles were observed [36-41]. In addition to staining
for activated microglia exclusively, we also stained sections
with ionized calcium-binding adapter molecule-1 (Iba-1) a
marker for all microglia. The results of this are shown in
Figure 3I and 3J, where it is seen that the percentage of
amoeboid cells is higher in the hemisphere injected with
fibrin γ377-395 peptide.
The results for injection of the unconjugated peptide
revealed a different pattern: In contrast to the conju-
gated peptide, while the number of activated microglia
increased with age, no significant changes were found
between the saline and unconjugated peptide-injected
conditions (Figure 3, bottom rows). These results are
summarized in Figure 4B. While a significant difference
was found for age (F = 6.56; df = 1,54; p ≤ 0.05), no sig-
nificant differences in the number of activated microglial
cells when compared with saline controls (F = 0.002;
df = 1,54; NS; No significant interaction was found be-
tween age and treatment: F = 3.89, df = 1,54; NS). We in-
terpret these results to mean that the unconjugated
peptide was ineffective at reducing the rate of activation
of microglial cells.
Effects of microglial inhibition on hypersphosphorylated
tau and NFTs
After establishing a practical method of delivery for the
inactivation of microglia in the transgenic mice model,
we sought to determine whether microglial inhibition af-
fected the accumulation of hyperphosphorylated tau in
neocortical neurons. After injecting the fibrin γ377-395
peptide-conjugated γ-Fe2O3 nanoparticles, the average
hyperphosphorylated tau per area surrounding the site
of injection was quantified using AT8 antibody staining
(Figure 5). Overall, no significant differences were found
in the number of cells containing hyperphosphorylated
tau (white arrows) in the fibrin-injected brain areas
Figure 2 Localization of the fibrin γ377-395 peptide-conjugated γ-Fe2O3 nanoparticles in the frontal cortex. The γ-Fe2O3 nanoparticles
were stained with potassium ferocyanide (blue). No staining was seen in the hemisphere injected with saline (A, C) and free fibrin γ377-395
peptide (B). Positive staining (D) (arrows) indicates the presence of the nanoparticles. Scale bar: 50 μm.
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hemispheres (F = 0.05;df = 1,289;NS). A significant differ-
ence was found for age (F = 4.22; df = 1,289; p ≤ 0.05). A
significant interaction effect was found between age and
treatment: (F = 29.5; df = 1,289; p ≤ 0.05), revealing an
opposing effect between the “young” and “old” mice fol-
lowing microglial inhibition on the accumulation of
hyperphosphorylated tau in cortical neurons. Compared
to controls, at age 3.5 months, an increase in the num-
ber of cells containing hyperphosphorylated tau was
found following microglial inhibition, whereas at age 6
months a decrease in the number of cells containing
hyperphosphorylated tau was observed. The results are
summarized in the graph in Figure 5. These results sug-
gest that the involvement of microglia in the develop-
ment of hyperphosphorylated tau is age-dependent or
alternatively, dependent on the stage of pathological tau
accumulation.
We then tested the effects of microglial inhibition
on the number of tangle-containing neurons. The ef-
fect of the fibrin γ377-395 peptide-conjugated γ-Fe2O3
nanoparticles on tangle formation in the frontal cor-
tex is shown in Figure 6. The results are similar tothose for the hyperphosphorylated tau. A significant in-
crease is found in the number of tangle-containing neu-
rons (white arrows) with age (F = 860; df = 1,366; p ≤ 0.05).
The effect of microglial inhibition is significant overall
(F = 88.96; df = 1,366; p ≤ 0.05). Again, a significant inter-
action between age and treatment was found: (F = 136;
df = 1,366; p ≤ 0.05). Post hoc comparisons revealed that
the differences in tangle-containing neurons between con-
trol and treated animals at 3.5 months were non signifi-
cant, which is not surprising given the very low number of
tangles occurring in neocortex at this age in the model.
The significant reduction in tangle-containing neurons
between control and treated animals occurred only at the
age at which significant tangle aggregation occurs in this
model. The results are summarized in the graph in
Figure 6.
Taken together, these results reveal that microglial in-
hibition reduces both hyperphosphorylated tau-containing
neurons and tangle-containing neurons in older mice.
However, hyperphosphorylated tau-containing neurons
are increased in younger mice, indicating that the effects
of microglial inhibition depend on the stage of the
pathological accumulation of tau.
Figure 3 Fibrin γ377-395 peptide-conjugated γ-Fe2O3 nanoparticles decreased the number of activated microglia. rTg4510 mice at ages
3.5 (A, B, E, F) and 6 months (C, D, G, H) were injected given a single intracranial injection unilaterally with saline (left column) or fibrin γ377-395
peptide-conjugated γ-Fe2O3 nanoparticles (B, D) or free fibrin γ377-395 peptide (F, H) and were sacrificed after 30 days. Activated microglial cells
were stained with the lectin IB4 (white arrows). DAPI was used for nuclear staining. Statistical analysis (see Figure 3) revealed a significant
reduction in the number of activated microglia following injection with fibrin γ377-395 peptide-conjugated γ-Fe2O3 nanoparticles (compare B and
D with A and C). Scale bar: 50 μm. I, J; Iba-1 staining demonstrates resting and activated microglia. I: saline injection; J: following injection with
fibrin γ377-395 peptide-conjugated γ-Fe2O3 nanoparticles. The differences in shape of the microglia are clearly seen. Scale bar: 25 μm.
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Figure 4 The effect of fibrin γ377-395 peptide-conjugated γ-Fe2O3 nanoparticles on the number of activated microglia. Statistical analysis
was performed using 2-way ANOVA followed by Tukey multiple comparison test. Area count of the stained microglia for IB4 showed a significant
decrease in the number of activated microglia at both ages when fibrin γ377-395 conjugated to nanoparticles was injected compared to saline
(A) (at age 3.5 months: n = 5 mice, 171 areas; at age 6 months: n = 6, 108 areas). Although there was a significant effect for age, no significant
differences were found between free fibrin γ377-395 and saline injections (B) (at age 3.5 months: n = 2 mice, 20 areas; at age 6 months: n = 3,
38 areas).
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The role of microglia cells in tau pathology is still an
open question, and the literature is filled with seemingly
contradictive findings on this subject. Previous studies
[21,42] have shown that dystrophic rather than activated
microglial cells are associated with tau pathology. On
the other hand, other studies described that chronic in-
flammation, caused by a high level of microglial activa-
tion, may exacerbate neurodegeneration [26,43]. For
example, Yoshiyama et al. [24] have recently shown thatadministering immunosuppressors reduced tau path-
ology when mice were treated at an early age for a
period of over 8 months.
In light of these contrasting findings we decided to spe-
cifically inhibit the activation of microglia cells to rule out
systemic factors arising from immunosuppressor treat-
ments. The inhibition was facilitated using fibrin γ377-395
peptide-conjugated γ-Fe2O3 nanoparticles, which signifi-
cantly decreased the number of activated microglial cells as
compared to the administration of the free peptide in both
Figure 5 (See legend on next page.)
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Figure 5 The effect of microglial inhibition on hyperphosphorylated tau is age dependent. Staining of hyperphosphorylated tau by AT8
revealed significant differences in neurons containing hyperphosphorylated tau. At age 3.5 months injecting the conjugated fibrin γ377-395
peptide (B) led to an increase in the number of cells containing hyperphosphorylated tau compared with control (A), (n = 5 mice, 160 areas). In
contrast, at age 6 months, a decrease in the number of hyperphosphorylated tau was observed when comparing the conjugated fibrin γ377-395
peptide (D) with control (C), (n = 6 mice, 133 areas). Scale bar: 50 μm.
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conjugating of fibrin γ377-395 peptide to the γ-Fe2O3
nanoparticles, which may have increased the stability of
the peptide against proteolytic enzymes present in the
body, thus prolonging its activity, compared to that of the
free peptide. A similar stabilization effect was reported pre-
viously for thrombin [39], glial-cell derived neurotrophic
factor [40], bFGF [36], TRAIL [37], factor VIIa [41], and
methotrexate [38] conjugated to γ-Fe2O3 nanoparticles.
Our results indicate that the stage of pathology may
affect microglial function in relation to the disease process,
revealed by the interaction between age and treatment for
hyperphosphorylated tau, where an inverse relationship
between the number of hyperphosphorylated tau and age
of treated mice was reported. In “young” mice an increase
in the number of cells containing hypersphosphorylated
tau was found, whereas in “old” mice a significant decrease
in hyperphosphorylated tau containing neurons was ob-
served. These findings suggest that the microglial cells
possess both a beneficial and a harmful role in the path-
ology of tau depending on the stage of the pathology. We
postulate that this effect is a result of two different stages
of the pathology: the early stage, when the microglial cells
attempt to remove cellular debris before further damage
can occur [44] and when they release neurotrophic factors
such as NGF, NT-3 and BDNF which have been demon-
strate to be neuroprotective [23]; and the late stage of the
pathology, when the microglia cells are over activated and
excessive levels of pro-inflammatory cytokines are released
[45]. The cytokines secreted mainly by activated microglia,
namely, interleukine-1 (IL-1), TNF-α, and interleukin-6
(IL-6), could affect the normal behavior of neurons and ex-
acerbate tau pathology [46]. Several studies have described
that IL-1 [43,47] and IL-6 [46] can induce phosphorylation
of tau in neuronal cells, further strengthening this
suggestion.
In “young” mice, our study found no differences in
NFTs count between mice treated with the fibrin γ377-395
peptide-conjugated γ-Fe2O3 nanoparticles and the con-
trol, whereas in “old” mice a significant reduction in the
number of cells containing NFTs was observed. This
significant finding is in accordance with a pre-vious
study [48] which described that tau is first hyper-
sphosphorylated and then aggregated into NFTs at a
later stage, rather than hyperphosphorylated tau accu-
mulation and tangle aggregation occurring in separate
populations of cells.Conclusions
This study has shown that microglial cells posses a com-
plex relationship with neuropathology. Our work dem-
onstrates that microglial cells can be an effective and
perhaps necessary target for therapeutic strategies. Simi-
lar evidence has been found in mouse models of
amyloid-β pathology [49,50]. Depending on the stage of
the disease, it may be necessary to use a differential ap-
proach to microglial activation: increasing activation at
early stages and reducing activation at later stages. This
has important implications for immunotherapeutic ap-
proaches to many neurodegenerative diseases in addition
to tauopathies.
This study has also shown the efficacy of γ-Fe2O3
nanoparticles in the stable delivery of fibrin γ377-395 pep-
tide to nervous tissue in vivo. This method can be used
for the study of delivery of a number of substances to
the brain, as well as monitoring their presence over time.
In addition to use as a tool for experimental drug deliv-
ery, it may also be possible to use γ-Fe2O3 nanoparticles
as a therapeutic approach for controlled release of sub-
stances in the central nervous system.
Materials and methods
Synthesis of bioactive γ-Fe2O3 nanoparticles
The following analytical-grade chemicals were purchased
from commercial sources and used without further puri-
fication: ferrous chloride tetrahydrate, hydrochloric acid
(1 M), sodium hydroxide (1 M standard solution), sodium
chloride, sodium nitrite, gelatin from porcine skin, divinyl
sulfone (DVS), triethylamine (TEA) from Sigma (Israel);
fibrinogen-derived γ377-395 peptide from AnaSpec (Israel);
Bicarbonate buffer (BB, 0.1 M, pH 8.4) and phosphate-
buffered saline (PBS free of Ca+2 and Mg+2, 0.1M, pH 7.4)
from Biological-Industries (Israel); midi MACS mag-
netic columns from Miltenyi Biotec GmbH (Germany).
Water was purified by passing deionized water through
an Elgastat Spectrum reverse osmosis system (Elga,
High Wycombe, UK).
γ-Fe2O3 and DVS-derivatized γ-Fe2O3 nanoparticles
were prepared according to our previous publications
[36]. The covalent conjugation of fibrin γ377-395 peptide
to the γ-Fe2O3 nanoparticles was accomplished via the
Michael addition reaction [36]. Briefly, 50 μl of a fibrin
γ377-395 peptide PBS solution (1 mg/ml, pH 7.4) were
added to 143 μl of the DVS-derivatized γ-Fe2O3
nanoparticles dispersed in BB (3.5 mg/ml, pH 8.4) at a
Figure 6 (See legend on next page.)
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Figure 6 The effect of microglial inhibition on NFTs. Staining of NFTs by Thioflavin-S revealed a reduction in neurons containing NFT in mice
aged 6 months when comparing saline (C) with fibrin γ377-395 peptide-conjugated γ-Fe2O3 nanoparticles (D) (n = 8 mice, 124 areas). No
differences in NFTs were found in mice aged 3.5 months when comparing saline (A) with the treatment hemisphere (B) (n = 4 mice, 246 areas).
Scale bar: 50 μm.
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mixture was then shaken at room temperature for 18 h.
Blocking of the residual double bonds was then accom-
plished by adding 1% glycine (w/v) and then shaking for
an additional hour. The obtained fibrin γ377-395 peptide-
conjugated γ-Fe2O3 nanoparticles were than washed
from non-magnetic waste with PBS using the high gradi-
ent magnetic field (HGMF) technique [34]. The concen-
tration of the γ377-395 peptide conjugated to the
nanoparticles was determined by measuring the un-
bound peptide using the Bradford assay and subtracting
it from the initial concentration [51].Animal model
rTg4510 mice were used in this study. Santa Cruz et al.
[52] created these transgenic mice using a CaMII alpha
promoter driven by a tetracycline operator to focus hu-
man mutant P301L tau over-expression in the forebrain
(hippocampus and higher cortical layers) of the mice.
Nine rTg4510 mice aged 3.5 months (“young”) and 7
rTg4510 aged 6 months (“old”) were used in this study.
Mice weight, on average, was 25g. All procedures were
performed in accordance with the NIH Guide for the
Care and Use of Laboratory Animals, and with the Bar-
Ilan University guidelines for the use and care of labora-
tory animals in research, approved and supervised by the
Institutional Animal Care and Use Committee.Intracranial injections
3.5 and 6 month old rTg4510 mice were injected intra-
cranially with the fibrin γ377-395 peptide-conjugated γ-Fe
2O3 nanoparticles and free fibrin γ
377-395 peptide (1:3
weight ratio). Briefly, mice were anaesthetized before
surgery with a ketamine:xylazine at 150 and 12 mg/kg,
respectively [53]. The animals were then placed into a
stereotaxic apparatus with a heating pad to maintain
body temperature. Stereotaxic coordinates were bregma +
1.5 mm anterior-posterior, 1.5 mm lateral and 1.8 mm
vertical for frontal cortex. Subsequently, 10 μL of the fi-
brin γ377-395 peptide-conjugated γ-Fe2O3 nanoparticles
dispersed in PBS (2 mg/ml, 10 ug bound fibrin γ377-395
per injection) and free fibrin γ377-395 peptide dissolved
in a PBS solution (3 mg/ml), were intracranially injected
in the right and left hemispheres, respectively. The in-
jection holes were then filled with bone wax. The mice
were stitched and then returned to their cages. All mice
used in our experiments were then sacrificed 30 dayspost injection via an intracardial perfusion described in
the next section.
Tissue preparation
The animals were given a lethal dose of thiopental so-
dium solution and were perfused intracardially with iso-
tonic PBS (pH 7.3) followed by 4% paraformaldehyde
solution in 0.1M PBS. Once the perfusions were
complete, the brains were rapidly removed from the
skulls and were placed in a 4% paraformaldehyde solu-
tion for post-fixation of at least 24 h at 4°C. After 24 h,
the brains were transferred to a 30% sucrose solution for
two days. The brains were then frozen in dry ice and
placed in −80°C over night. Before sectioning the brains
with a cryostat, the brains were covered using an opti-
mal cutting temperature (OCT) solution and were
placed in −20°C. Once the OCT solidified, the brains
were placed in the cryostat with the frontal side up. Tis-
sue samples were selected from areas of cortex adjacent
to the injection sites. The brains were sliced to 25 μm
coronal sections. Each sample consisted of 5 slices. Con-
trols were the contralateral areas. Sampling within the
slices was performed at 3 sites, each 400 × 340 μm. The
brain sections were then individually picked up using a
paint brush and were transferred to a well filled with
0.1M PBS. Slices were then either stained immediately
following the appropriate protocol or stored in a cryo-
protectant solution at −20°C until further use.
Staining methods
Lectin staining
The slices were first introduced into a PBS solution in
order to remove the OCT from the tissue. The slices
were treated with FITC-conjugated Bandeiraea simpli-
cifolia isolectin B4 (IB-4; 1:50; Sigma-Aldrich) for 1 h,
and then were washed three times for 5 min each in
PBS. The slices were then mounted on slides and stored
in the dark to air-dry. A drop of DAPI (1:2000; Sigma-
Aldrich) solution was added to sections after drying
using a Pasteur pipette for 1 min and washed twice for 1
min each in PBS. The slides were then sealed using a
cover slip.
Iron staining
The slices were mounted on slides and placed in 2% po-
tassium ferrocyanide solution with 2% HCl solution for
30 min. Afterwards, the slides were washed three times
in distilled water and sealed with a cover slip.
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The slices were first introduced into a PBS solution in
order to remove the OCT from the tissue. The slices
were incubated in 0.5% Triton for 20 min and then
washed three times for 5 min each in PBS. The slices
were then incubated in a blocking solution (NGS, 5% in
PBS; from Jackson Immuno Research) for 1 h. After the
blocking stage, slices were treated with Anti-Human-
PHF-Tau Monoclonal Antibody (AT8; 1:1000 in normal
goat serum; Thermo Scientific) and then left overnight
at 4°C. Following incubation, the slices were washed
three times for 5 min each in PBS. The slices were
treated with Cy3 donkey anti-mouse (Cy3 1:500, Jackson
Immuno Research). After 1 h, the slices were washed
three times in PBS. The slices were then mounted on
slides, stored in the dark to air-dry and then sealed using
a cover slip. If NFTs staining was performed as well, a
drop of 0.05% Thio-S solution (Sigma-Aldrich) was
added to sections after drying using a Pasteur pipette.
The sections were then incubated for 8 min in the dark,
followed by two washes for 10 sec in 80% ethanol solu-
tion and one wash in distilled water. The slides were
then stored in the dark to air-dry and sealed using a
cover slip.
To study microglia morphology, Iba-1 staining was
performed. The endogenous peroxidase was blocked by
10% H2O2, 0.01% Triton X-100 in PBS, and 3% Metha-
nol. After 30 minutes blocking was performed by 20%
NGS for 1 h. Slices were then incubated overnight in
rabbit polyclonal anti-IBA1 antibody (1:250; Wako
Chemicals) with 2% NGS. Following incubation the sec-
tions were treated with a secondary antibody, Anti rabbit
IgG Peroxidase (1:200; Santa Cruz) for 1 h followed by
incubation with ABC solution (Vector) for 30 minutes.
The peroxidase labeling was visualized by incubation
with commercial DAB Substrate Kit (Vector) for a few
minutes. The reaction was stopped by placing the slices
in PBS. Slices were then mounted, dehydrated, and
cover-slipped.
Statistical analysis
Two to three different areas surrounding the site of injec-
tion from five slices from each mouse were defined for the
analysis of activated microglial cells and cells containing
hypersphosphorylated tau and NFTs. Statistical analysis
was performed using 2-way-ANOVAs followed by Tukey
multiple comparison tests. A significance level of p ≤ 0.05
was set for all statistical tests.
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